Jasper Therapeutics

Jasper Therapeutics company information, Employees & Contact Information

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.

Company Details

Employees
67
Address
Redwood City, Ca, Us
Phone
415-946-1087
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Redwood City, CA
Looking for a particular Jasper Therapeutics employee's phone or email?

Jasper Therapeutics Questions

News

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - Yahoo Finance

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria Yahoo Finance

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Jasper Therapeutics Announces Pricing of $30 Million Public - GlobeNewswire

Jasper Therapeutics Announces Pricing of $30 Million Public GlobeNewswire

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria - Yahoo Finance

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria Yahoo Finance

Jasper Therapeutics Announces Proposed Public Offering of - GlobeNewswire

Jasper Therapeutics Announces Proposed Public Offering of GlobeNewswire

$30 Million Capital Raise: Biotech Jasper Therapeutics Prices Stock Offering to Advance Mast Cell Disease Drug - Stock Titan

$30 Million Capital Raise: Biotech Jasper Therapeutics Prices Stock Offering to Advance Mast Cell Disease Drug Stock Titan

Patients with chronic inducible urticaria see complete response to briquilimab at 6 weeks - Healio

Patients with chronic inducible urticaria see complete response to briquilimab at 6 weeks Healio

Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development - Quiver Quantitative

Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development Quiver Quantitative

Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting - Nasdaq

Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting Nasdaq

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway - GlobeNewswire

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway GlobeNewswire

Clinical-Stage Biotech Jasper Therapeutics Launches Stock Offering to Advance Novel Mast Cell Disease Treatment - Stock Titan

Clinical-Stage Biotech Jasper Therapeutics Launches Stock Offering to Advance Novel Mast Cell Disease Treatment Stock Titan

Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab - Healio

Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab Healio

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments - Yahoo Finance

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments Yahoo Finance

Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire

Jasper Therapeutics Announces Briquilimab Presentations at GlobeNewswire

Jasper Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Jasper Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria - GlobeNewswire

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria GlobeNewswire

Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID - Business Wire

Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID Business Wire

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation - Business Wire

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation Business Wire

Top Jasper Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant